1 TITLE PAGE

2 FULL TITLE

- 3 An outbreak of Chagas disease through oral transmission: 115 years after discovery by
- 4 Carlos Chagas, the disease is still hard to manage.

5 SHORT TITLE

6 Oral Chagas disease outbreak: 115 years onwards, still hard to manage.

7

8 AUTHORS AND AFFILIATIONS

- 9 Eudes Alves Simões-Neto¹, Daniel Wagner de Castro Lima Santos², Maria Rosa
- 10 Quaresma Bomfim³, Jackson Maurício Lopes Costa⁴, Amanda Ferreira Simões⁵, Lucas
- 11 Dias Vasconcelos¹, Domingos Carvalho Sodré⁴, Ana Cleide Mineu Costa⁴, Samuel Vieira
- 12 Rodrigues Dumont⁴, Bruna de Oliveira de Melo³, Conceição de Maria Pedrozo e Silva de
- 13 Azevedo⁶.
- ¹ Federal University of Maranhão (UFMA), Pinheiro, Maranhão, Brazil.
- ² Presidente Dutra University Hospital (HU-UPD), Brazilian Company of Hospital Services
- 16 (EBSERH), Federal University of Maranhão (UFMA), Brazil. D'or Research and Teaching
- 17 Institute (IDOR), Brazil.
- 18 ³Ceuma University (UNICEUMA), São Luís, Maranhão, Brazil.
- ⁴ State Health Department of Maranhão (SES/MA), São Luís, Maranhão, Brazil.
- ⁵ Brasília University Hospital (HUB), Brazilian Company of Hospital Services (EBSERH),
- 21 Brasília University (UnB), Brasília, Brazil.
- ⁶ Federal University of Maranhão (UFMA), São Luís, Maranhão, Brazil.

23

24 Corresponding author:

- 25 Eudes Alves Simões-Neto.
- 26 e-mail: eudesimoes@gmail.com; eudes.simoes@ufma.br
- 27 ORCID: <u>https://orcid.org/0000-0001-5449-5908</u>
- 28

29 Author contributions

- 30 Eudes Alves Simões-Neto: Conceptualization, Data curation, Methodology, Formal
- 31 analysis, Investigation, Data curation, Writing-original draft, Writing-review and editing,
- 32 Project administration, Visualization; Daniel Wagner de Castro Lima Santos:
- 33 Methodology, Validation, Writing-review and editing. Maria Rosa Quaresma Bomfim:
- 34 Methodology, Investigation, Resources, Validation, Writing-review and editing; Jackson
- 35 Maurício Lopes Costa: Conceptualization, Investigation; Amanda Ferreira Simões:
- 36 Investigation, Visualization; Lucas Dias Vasconcelos: Writing-original draft; Domingos
- 37 Carvalho Sodré: Investigation; Ana Cleide Mineu Costa: Investigation; Samuel Vieira
- 38 Rodrigues Dumont: Investigation; Bruna de Oliveira de Melo: Investigation; Conceição
- 39 de Maria Pedrozo e Silva de Azevedo: Conceptualization, Formal analysis, Supervision,
- 40 Project administration, Validation, Writing-review and editing.

41

42 ABSTRACT

43 Background:

Orally transmitted acute Chagas disease (ACD) mostly affects low-visibility and lowincome individuals, mainly in tropical and subtropical zones. However, even more than 100
years after Carlos Chagas' discovery, several difficulties in managing ACD are still faced.

47 Ita expansion to other, non-endemic areas through globalization processes has48 transformed it into a global health problem.

49 Methodology and findings:

50 This report addresses an outbreak of 39 cases of ACD due to oral transmission. A clinical-51 epidemiological investigation with an entomological search was performed. Laboratory 52 criteria (positive peripheral blood smear (PBS), seroconversion of IgG and 2x increase in 53 IgG titer) and clinical-epidemiological criteria (clinical findings, epidemiological exposure 54 and at least one positive IgG) were used for diagnoses. In-house conventional polymerase 55 chain reaction (PCR) was performed on 33 samples. All patients were treated with 56 benznidazole. After 4.5 years, IgG was investigated in 26 individuals. Their mean age was 57 33.6 years, with no difference in gender distribution; the mean incubation period was 13.8 58 days and mean time between symptom onset and treatment was 16.6 days. The most 59 frequent symptoms were fever and lymphadenopathy (90%). For 66.6%, laboratory criteria 60 yielded the diagnosis and for 23%, clinical-epidemiological criteria, while 10.2% showed 61 negative tests but were treated due to high clinical suspicion. Test positivity rates: PBS 62 69.7%; serology 91.4%; PCR 100%. There were no deaths. Serological cure was achieved 63 for 34.6% and decreased IgG titers for 15.3%.

64 **Conclusions and significance:**

We present all the barriers encountered in managing real-life situations: vulnerability of the population; dependence on old diagnostic techniques; lack of standardization of molecular biology techniques; and few therapeutic options. We demonstrated the importance of rapid surveillance action with early treatment, such that this outbreak did not give rise to deaths. We also propose that conventional PCR should become standardized within the diagnostic routine.

71

72 KEYWORDS

73 Chagas disease, Trypanosoma cruzi, food-borne disease, polymerase chain reaction,

74 disease outbreaks, neglected disease

75

76 AUTHOR SUMMARY (150-200 words)

77 In this study we present an outbreak of orally transmitted acute Chagas disease (ACD), a 78 neglected tropical disease. The source of transmission was bacaba juice served at a 79 celebration held in a quilombola community and 39 individuals were affected. The focus of 80 this study was clinical-epidemiological investigation and diagnostic tools. There were no 81 deaths due to this event, probably because of the quick action of the surveillance team 82 and the early start of treatment. We show all the difficulties facing a real-life situation 83 (vulnerability of population affected, weaknesses regarding good food safety practices and 84 obstacles to following what guidelines recommend), discuss the performance and 85 executability of the diagnostic method used and address the global threat that Chagas 86 disease may pose. Furthermore, we propose that the polymerase chain reaction should 87 become standardized in diagnosing acute disease, given that this was the only method 88 with 100% positivity, even among patients whose other tests were all negative.

89

90 **1. Introduction**

Chagas disease (CD) is a chronic systemic anthropozoonosis in the Americas caused by *Trypanosoma cruzi*, a hemoflagellate intracellular parasite discovered in 1909 [1,2].
American trypanosomiasis is classified by the World Health Organization (WHO) as one of
the 20 neglected tropical diseases (NTDs) and it affects low-visibility and low-income

95 individuals and populations in developing countries, mainly in tropical and subtropical
96 zones [3]. Furthermore, its status as a NTD means that controlling or eradicating it by
97 applying public health strategies remains possible, even though it has been neglected by
98 laboratories, pharmaceutical companies and local governments.

99 Even 115 years after the little girl Berenice and the publication [4,5,6,7] of Carlos Chagas' 100 work, in which he describes the etiological agent, some domestic and wild reservoirs, the 101 vector, the life cycle, clinical manifestations and complications of the disease, CD 102 continues to be endemic in Latin American countries, especially in Brazil, Argentina, 103 Mexico, Bolivia and Chile. Although the prevalence rate per 100,000 population decreased 104 in many countries between 1990 and 2019, in Brazil an increase of 12.8% in the estimated 105 number of cases was observed over this period [8]. The high numbers of disability-106 adjusted life-years (DALYs), years of life lost (YLLs) and years lived with a disability 107 (YLDs) due to CD worldwide are still challenging. Curiously, a decrease in DALYs was 108 observed in Brazil over the same period, although a representative magnitude for society 109 remained [8,9].

110 Over the past few decades, enhanced vector control programs and mandatory screening 111 for blood transfusions have decreased the burden of this disease in Latin America [3]. 112 However, while the typical vectorial transmission route has become controlled, the other 113 forms of acquiring the disease have represented a challenge over the last 20 years. Food-114 borne transmission has gained great importance, as it can cause outbreaks secondary to 115 contamination of food and beverages and because of its pathophysiology and clinical 116 features [10]. The vector most frequently associated with this route is Panstrongylus 117 geniculatus, and transmission through this route occurs when whole triatomines or their 118 feces carrying metacyclic trypomastigotes of T. cruzi taint juices made from sugar cane,

bacaba, açaí or palm wine. Transmission through ingestion of infected wild-animal meatsalso occurs [1,10,11,12].

121 Currently, oral infection with T. cruzi is the most important transmission route in Brazil. 122 Several outbreaks have especially been documented in the Amazon region (states of Pará 123 and Amazonas), and in some states in the northeastern and southern regions. 124 Furthermore, the trend over the years has been increasing [13]. This oral transmission 125 represents a major challenge for implementation of resolution CD49.R19, created by the 126 49th Directing Council of PAHO in 2009, which promotes the elimination or reduction of 127 neglected diseases and other related poverty diseases, including Chagas disease in all its 128 forms of presentation [14].

129 Regarding diagnosis, there are still major challenges ahead. Some tools standardized 130 through international guidelines are difficult to use and require several samples, and many 131 of them are archaic. For chronic Chagas disease (CCD), use of two different serological 132 tests continues to be recommended (enzyme-linked immunosorbent assay – ELISA, 133 hemagglutination inhibition assay – HAI, or indirect immunofluorescence – IIF). In limited-134 resource settings or difficult-to-access areas, a single ELISA test may be considered, but 135 requires confirmation with another test prior to starting treatment [15]. Over recent years, 136 some studies have presented encouraging results regarding the performance of rapid tests 137 (immunochromatographic) for diagnosing CCD [16,17]. However, for acute Chagas 138 disease (ACD), we continue to rely on microscopy (with variable sensitivity) and 139 conventional immunological tests, both often requiring several samples. To date, there is 140 no standard for molecular biology techniques for diagnosis, such as the polymerase chain 141 reaction (PCR), and these techniques are restricted to surveillance laboratories and 142 research centers [18]. There is also currently no point-of-care test for diagnosing ACD.

143 The treatment options for Chagas disease are even more restricted. The two trypanocide 144 drugs available, benznidazole and nifurtimox, have been used for over 50 years. However, 145 due to the long-term treatment (60 to 90 days) and high frequency of side effects (about 146 40%), there is a high dropout rate [19,20]. Some initiatives in this field deserve to be 147 highlighted, such as Drugs for Neglected Disease (DNDi), which helped to develop the first 148 formulation of benznidazole for pediatrics, in addition to promoting studies with lower 149 doses and shorter treatment time [21.22]. However, many more actions are necessary in 150 order to achieve the greater objective: a highly effective medication, with low cost, shorter 151 treatment time and fewer side effects.

152 The present study evaluates the clinical-epidemiological characteristics and diagnostic 153 aspects of an autochthonous outbreak of ACD due to oral transmission that occurred in 154 the state of Maranhão, Brazil, which had previously not been considered an area of high 155 prevalence or high risk of disease transmission. We have described the epidemiological 156 surveillance and diagnostic methods, including molecular tools, and discussed the genetic 157 analysis of *T. cruzi*. These data have allowed us to better understand the risks associated 158 with transmission, as well as the diagnostic and therapeutic challenges involved in the 159 standard treatment available in Brazil.

160

161 **2. Methods**

This was a prospective cohort study in which patients with ACD from an outbreak due tooral transmission were followed up for 4.5 years.

164 2.1. Ethical statements: Formal written consent was obtained from al the patients
165 and the parent/guardian in case of children. Ethics approval for this study was

166 obtained from the University Hospital Research Ethics Committee of the Federal

167 University of Maranhão, through protocol number 4.357.642.


- 168 2.2. Population evaluated and period: The study involved 39 patients with ACD
 169 from the same outbreak. The information relates to the period during which the
 170 outbreak occurred (2018) and another period 4.5 years later (2022).
- 171 2.3. Clinical evaluation: The following were investigated: incubation period, time
 172 taken to initiate the therapy, duration of therapy and clinical findings (fever,
 173 asthenia, chills, myalgia, facial edema, dyspnea, headache, cough, abdominal
 174 pain, lower limbs edema, thoracic pain, diarrhea and inoculation chagoma).
- 175 2.4. **Diagnostic criteria and tools:** To define ACD cases, diagnostic criteria already 176 established in the literature and guidelines were used: (a) laboratory criteria (at 177 least one of the following tests: positive direct microscopic examination of 178 peripheral blood smear, seroconversion of IgG or 2x increase in IgG titer with at 179 least 15 days interval); (b) clinical-epidemiological criteria (clinical findings, 180 epidemiological exposure and at least one positive IgG finding). The direct 181 microscopic examination consisted of use of the technique of blood smears from 182 peripheral blood with Giemsa staining from Merck®; and the serological tests 183 used were ELISA from Bioclin®, IIF from Bio Manguinhos® and HAI from Wama 184 Diagnostica®. It was not possible to perform the IgM test due to lack of 185 resources and the inherent difficulty in the technique. Additionally, in house 186 conventional PCR was performed on 33 of the 39 stored samples. A description 187 of the storage of samples and PCR steps is presented as supplementary data 188 (Supporting information).

189 2.5. Epidemiological surveillance: An investigative process was conducted, 190 consisting of interviews among the local population, observation of the 191 production process of the drink involved in the outbreak and distribution of 192 triatomine information stations (Portuguese acronym PIT) for six months. PITs 193 are a strategy used by the Oswaldo Cruz Foundation (FIOCRUZ) to monitor 194 vectors. They consist of boxes containing visual information about triatomine 195 species that are distributed across the localities of concern. These boxes are 196 disseminated among the population. Whenever a resident finds a suspicious 197 arthropod, they deposit it in a PIT and report this finding to surveillance workers, 198 who, in turn, analyze the insect and look for *T. cruzi* in its feces.

- 199 2.6. Treatment: All 39 patients were treated with benznidazole: adults with 5
 200 mg/kg/day (maximum of 300 mg/day) and children with 5-10 mg/kg/day, for at
 201 least 30 days.
- 202 2.7. Long term follow-up: After an interval of 4.5 years, serological tests (ELISA
 203 and IIF) were performed on 26 patients. The others were lost to follow-up
 204 because they had changed their place of residence to another state.
- 205 **3. Results**
- 206 3.1. Outbreak report

In February 2018, a sexagenarian woman from a quilombo community, in Maranhão state,
Brazil, who had previously been admitted to and discharged from a municipal hospital
twice, with two negative malaria blood smears, came to the Regional Epidemiological
Surveillance Center of Pinheiro, Maranhão, Brazil, to undergo a third malaria blood smear.
The patient had an 11-day history of abdominal pain, myalgia, asthenia, chills and fever in
the late afternoon. The first two tests, previously found to be negative for malaria, were

- 213 reviewed. Both of them tested positive for trypomastigote forms of T. cruzi, thus confirming
- 214 that the patient had ACD (Figure 1). She was treated with 300 mg/day of benznidazole and
- 215 became asymptomatic in less than a week.
- 216 Fig 1. Trypomastigote form of *T. cruzi* (arrow) in a peripheral blood smear stained
- 217 using the Giemsa stain technique, from the index case (optical microscopy, 700x
- 218 magnification).



219

220 An epidemiological investigation found that other people living in the same village also had 221 similar symptoms. Moreover, they all had attended a celebration on January 2018 (three 222 weeks earlier) at which bacaba juice was served, which was the likely transmission route. 223 Within two weeks after the first case, 85 people were evaluated and tested. An outbreak of 224 39 cases of ACD was diagnosed and treatment was started for all these individuals.

225 3.2.

Epidemiological investigation:

226 An investigation team was deployed to the area. The village is a guilombo community, 227 located in the municipality of Pedro do Rosário, state of Maranhão, northeastern Brazil 228 (Figure 2), in the pre-Amazon region. There was no paved road access. It is close to an 229 environmental protection area (EPA), the Baixada Maranhense EPA, which is a Ramsar 230 site.

231 Fig 2. Map of the geographic location of Pedro do Rosário, state of Maranhão,

232 northeastern Brazil.



233

234 The residents of this village live in extreme poverty, in mud houses (Figure 3) with no basic 235 sanitation (no sewage disposal system and no treated water) and with few healthcare 236 resources. The area is inhabited by several species that act as reservoirs of T. cruzi, but 237 the one most likely involved in this outbreak was the "mucura", a marsupial species of 238 opossum from the Didelphidae family, which has the habit of living or hiding in the palm 239 tree canopy. Triatomines, which feed on the blood of these mammals, also make their 240 home in the palm canopy. When the fruit is extracted and processed, the insects may be 241 accidentally crushed and those infected by *T. cruzi* end up contaminating the beverage.

242 Fig 3. Typical house (made of mud) in the outbreak location



243

244

245 *Oenocarpus bacaba* ("bacaba") is a palm tree native to the Amazon and its fruit resembles 246 that of *Euterpe edulis* ("juçara" or "açaí"). It can reach up to 20 meters in height and 20 to 247 25 centimeters in diameter (Figure 4). Its fruit is widely consumed in the region and is often 248 the only source of food for the local population. It is a tradition for this community to hold a 249 celebration every year during the bacaba seasonal period.

250 Fig 4. *Oenocarpus bacaba* palm tree (a) and fruit (b).



251

The juice production process is completely artisanal and does not follow good practices. The bacaba bunch is placed in a plastic bag on the ground where the fruits are removed. The fruits are then placed in a bucket of untreated water where it remains for a few minutes to remove excess straw and wood. The water is then removed, and the fruits are crushed by hand to extract the juice. The liquid is then passed through a sieve to remove the seeds and skins of the fruit. Finally, the liquid is slightly warmed over a wood fire, but does not reach boiling temperature. After cooling, the juice is served.

For the entomological investigation, triatomine information stations (Portuguese acronym PIT) were distributed throughout the community and kept there for six months. Through their use, 25 specimens of *Rhodnius pictipes* and two of *R. robustus* were found, all in

- 262 peridomestic areas, with an infection rate of 33.3% (Table 1). No specimens of any
- 263 species were found inside the houses.
- 264
- 265 Table 1. Quantities of triatomines captured and T. cruzi infection rate during the

266 outbreak period.

Months	Triatomines captured (n)	Triatomines positive for <i>T. cruzi</i> (n / %)
March	3	0 / 0
April	5	1 / 20%
Мау	3	1 / 33.3%
June	2	2 / 100%
September	6	2/33.3%
October	8	3/37,5%
Total	27	9/33.3%

267

268

269 3.3. Demographic, clinical and laboratory characteristics

270 The clinical and diagnostic characteristics of the outbreak are summarized in Table 2. The 271 patients' mean age was 33.6 years (ranging from 10 months to 78 years). There was no 272 difference in gender distribution (20 women and 19 men). The mean incubation period was 273 13.8 days (ranging from 2 to 28 days). The mean length of time between symptom onset 274 and treatment was 16.6 days (ranging from 6 to 54 days). The most frequent symptoms 275 were fever and lymphadenopathy (90%; 35/39), asthenia (56%; 22/39), chills (51%; 276 20/39), myalgia (48%; 18/39), facial edema and dyspnea (38%; 15/39) and headache and 277 cough (31%; 12/39).

			•••			•						•	
ID	SEX	Age range (years)	SYMPTOMS	Incubation (days)	Number of days between symptoms and blood smear	Blood smear result	PCR result	lgG ELISA result (1 st sample)	IgG IIF result (1 st sample)	lgG ELISA result (2 nd sample)	lgG HAI result (2 nd sample)	IgG ELISA result (4.5 years later)	IgG IIF resul (4.5 years later)
Pat	ients d	iagnosed	through laboratory cri	iteria: positive	parasitologica	l findings	OR sero	conversion	of IgG OR 2	x increase in	titers of IgG	IIF	
19	М	10-15	Fever, lymphadenopathy, asthenia, dyspnea, chest pain, facial edema	10	16	POS	POS	NEG	INDET 1/40	POS	INCONC	POS	POS 1/160
24	F	66-70	Fever in evening, lymphadenopathy, asthenia, cough, dyspnea, facial edema, diarrhea	15	11	POS	POS	INDET	INDET 1/40	POS	POS	-	-
39	F	66-70	Fever in evening, lymphadenopathy, chill, myalgia, asthenia, abdominal pain.	14	11	POS	-	NEG	POS 1/160	POS	POS	POS	INDE T 1/40
1	F	11-15	Fever in evening, lymphadenopathy, headache, asthenia, facial edema	17	15	POS	-	POS	POS 1/80	POS	POS	POS	POS 1/80
2	F	36-40	Fever in evening, lymphadenopathy, chill, dyspnea, facial edema, abdominal pain	14	11	POS	POS	POS	POS 1/160	POS	POS	POS	INDE T 1/40
3	Μ	56-60	Fever in evening, lymphadenopathy, asthenia, cough, dyspnea, diarrhea	4	19	POS	POS	NEG	NEG	NEG	NEG	NEG	NEG
8	М	31-35	Fever in evening, lymphadenopathy, chill, myalgia, asthenia	5	27	POS	POS	POS	POS 1/160	POS	POS	-	-
10	F	36-40	Fever in evening, lymphadenopathy, chill, cough, dyspnea, chest	14	17	POS	POS	POS	POS 1/80	POS	NEG	-	-

279 Table 2. Demographic, clinical and laboratory characteristics of 39 cases of acute Chagas disease

			pain, lower limb edema, inoculation chagoma??										
11	F	11-15	Fever in evening, lymphadenopathy, chill, headache, asthenia Headache,	19	13	POS	POS	POS	POS 1/80	INCONC	INCONC	-	-
12	F	36-40	asthenia, cough, dyspnea, facial edema Fever,	19	13	POS	POS	NEG	NEG	NEG	NEG	POS	POS 1/80
13	М	51-55	lymphadenopathy, chill, headache, myalgia, dyspnea, abdominal pain	2	30	POS	POS	POS	POS 1/80	POS	POS	-	-
15	М	26-30	Fever in evening, lymphadenopathy, chill, myalgia, asthenia	11	20	POS	POS	POS	POS 1/80	-	-	-	-
16	F	51-55	Fever in evening, lymphadenopathy, chill, cough, dyspnea, lower limb edema	12	20	POS	-	INDET	INDET 1/40	IND.	NEG	POS	POS 1/80
17	М	26-30	Fever, lymphadenopathy, chill, asthenia	18	13	POS	POS	NEG	INDET 1/40	-	-	-	-
18	F	11-15	Fever in evening, lymphadenopathy, headache, asthenia, facial edema Fever,	7	19	POS	POS	INDET	POS 1/80	-	-	-	
20	М	21-25	lymphadenopathy, chill, headache, asthenia, abdominal pain	15	11	POS	POS	POS	POS 1/80	POS	POS	-	-
21	М	56-60	Fever in evening, lymphadenopathy, cough, dyspnea, abdominal pain Fever,	10	16	POS	POS	POS	POS 1/160	POS	POS (IIF)	IND	NEG
22	F	26-30	lymphadenopathy, chill, headache, myalgia, cough, dyspnea, abdominal pain	13	18	POS	POS	POS	POS 1/80	POS	POS	POS	POS 1/80

23	Μ	11-15	Fever in evening, lymphadenopathy, headache, myalgia, cough, facial edema	7	19	POS	POS	POS	INDET 1/40	POS	POS	POS	POS 1/160
25	F	16-20	Fever, lymphadenopathy, myalgia, cough Fever in evening,	15	11	POS	POS	POS	POS 1/80	POS	POS	NEG	NEG
26	F	11-15	lymphadenopathy, headache, myalgia, facial edema, abdominal pain	10	16	POS	POS	NEG	NEG	INCONC	INCONC	POS	POS 1/80
27	F	31-35	headache, cough, dyspnea, facial edema, abdominal pain	17	15	POS	POS	POS	POS 1/80	POS	POS	POS	POS 1/80
32	F	1-5	Fever, lymphadenopathy, facial edema, abdominal pain, diarrhea	15	23	POS	POS	NEG	INDET 1/40	NEG	NEG	POS	POS 1/160
5	М	31-35	Fever in evening, lymphadenopathy, chill, myalgia, asthenia	16	-		POS	POS	INDET 1/40	POS	POS IIF 1/160	POS	POS 1/160
33	М	11-15	Fever, lymphadenopathy,	28	-	-	POS	NEG	POS 1/80	POS	POS	-	-
37	F	66-70	Chill at evening, asthenia, dyspnea, lower limb edema, facial edema	12	-	-	-	INDET	INDET 1/40	POS	POS	POS	POS 1/160
Pati	ents c	diagnosed	through epidemiologic	al criteria: clir	ical findings /	AND epide	emiologic	al link AND) at least one	positive IgG	6 finding		
4	М	26-30	Fever at evening, lymphadenopathy, chill, myalgia	5	26	NEG	-	POS	POS 1/80	POS	POS	NEG	NEG
6	М	36-40	Fever at evening, lymphadenopathy, chills, myalgia, asthenia	24	8	NEG	-	POS	POS 1/80	POS	POS	POS	POS 1/80
7	М	46-50	Fever, lymphadenopathy, asthenia	26	7	NEG	POS	POS	POS 1/80	POS	POS	NEG	NEG
9	М	26-30	Fever in evening, lymphadenopathy, headache, myalgia,	15	17	NEG	POS	POS	POS 1/160	POS	POS	POS	POS 1/80
14	М	1-5	asthenia, dyspnea Fever in evening,	13	13	NEG	POS	POS	INDET	POS	POS	POS	POS

			lymphadenopathy, chill, facial edema						1/40				1/80
28	М	46-50	Fever in evening, lymphadenopathy, chill, myalgia, asthenia	12	11	NEG	POS	POS	POS 1/160	POS	POS	POS	POS 1/80
29	М	21-25	Fever at evening, lymphadenopathy, chill, myalgia, asthenia	30		-	POS	POS	POS 1/160	POS	POS	-	-
34	F	31-35	Fever in evening, lymphadenopathy, chill, headache, myalgia, dyspnea, chest pain, lower limb edema, facial edema	16	7	NEG	POS	INDET	POS 1/160	INCONC	INCONC	NEG	NEG
38	F	41-45	Fever in evening, lymphadenopathy, myalgia, asthenia, edema MII, facial edema	7	-	-	-	POS	POS 1/80	-	-	-	-
Pati	ents v	vithout dia	agnostic criteria: clinical	findings ANI) epidemiolog	gical link A	ND nega	tive tests					
30	М	1-5	Fever Fever,	16	22	NEG	POS	NEG	NEG	NEG	NEG	NEG	NEG
31	F	11-15	lymphadenopathy, asthenia Fever in evening, lymphadenopathy,	13	-	-	POS	NEG	NEG	-	-	NEG	NEG
35	F	76-80	chill, myalgia, asthenia, cough, dyspnea, facial edema, abdominal pain	11	22	NEG	POS	NEG	NEG	NEG	NEG	-	-
36	F	61-65	Fever in evening, lymphadenopathy, asthenia, cough	15	16	NEG	POS	NEG	NEG	NEG	NEG	NEG	NEG

ID, patient identity number; M, male; F, female; PCR, polymerase chain reaction; ELISA, enzyme-linked immunosorbent assay; HAI, hemagglutination inhibition assay; IIF, indirect immunofluorescence test; POS, positive; NEG, negative; INDET, indeterminate; INCONC, inconclusive.

280

281 Out of the 39 cases, 66.6% (26/39) were diagnosed through laboratory criteria and 23% 282 (9/39) through clinical-epidemiological criteria, while 10.2% (4/39) had negative tests but 283 were considered to be cases of ACD due to high clinical suspicion. We performed one 284 peripheral blood smear, and also two sequential serological evaluations 50 days apart. 285 The positivity rates of the tests were as follows: peripheral blood smear in 69.7% (23/33) of 286 the cases; first serological sample in 66.6% (26/39) of the cases, and seroconversion OR 287 2x increase in IgG titer in 17.7% (6/35) of the cases. The overall positivity of the 288 serological tests was 91.4% (32/35). Sequential samples were not collected on time in the 289 cases of four patients.

290 All 33 samples (100%) amplified through PCR and sequencing with the specific primers 291 allowed us to identify T. cruzi. These included nine of the thirteen patients diagnosed 292 through clinical-epidemiological criteria and all four patients for whom all other test results 293 were negative. The sequences from these samples have been deposited in GenBank 294 under the following accession numbers: ON037202 to ON037234. Alignment of these 295 sequences with T. cruzi sequences previously deposited in GenBank showed a genetic 296 similarities ranging from 94.8 to 100.0% with samples from the state of Pará, which is 297 located in the northern region of Brazil. Through phylogenetic analysis (S1 Figure 1), it 298 was possible to ascertain the evolutionary relationships between our sequences and those 299 from GenBank, as detailed in the supplementary data (Supporting information).

All 39 patients were treated with benznidazole: adults with 5 mg/kg/day (maximum of 300 mg/day) and children with 5-10 mg/kg/day, for 60 days. Only two patients withdrew from the treatment before the end of the schedule, but they completed at least 30 days of treatment. One of them had to be hospitalized due to a drug reaction consisting of

eosinophilia and systemic symptoms (DRESS) syndrome, which was resolved with
 corticosteroids and antihistamines. There were no deaths due to this outbreak.

After an interval of 4.5 years, ELISA and IIF IgG were performed on 26 individuals, which showed that serological cure had been achieved (negative tests) in 34.6% of the cases (9/26), while decreased IgG titers were found in 15.3% of the cases (4/26). The other patients were lost to follow-up because they had changed their place of residence to another state.

311 4. **Discussion:**

Here, we present an epidemic outbreak of acute Chagas disease duo to oral transmission in a high-vulnerability population in the state of Maranhão, Brazil. It was the largest reported outbreak to date in this state.

In 2021, the Human Development Index (HDI) of the state of Maranhão was 0.676, the lowest in Brazil. Hunger, malnutrition, social exclusion and deficient basic sanitation are a hallmark of the state. More than 50% of the population lives on a per capita income of less than \$81 per month. Only 56.5% of the population of Maranhão has access to a piped water system and 43.5% do not have access to drinkable water [23].

320 All these associated factors have given rise to an explosion of endemic diseases in this 321 state, including increased numbers of cases and outbreaks of ACD. Until 2010, cases in 322 Maranhão were recorded only through the classic vectorial route in a predominantly wild 323 environment. Most cases of orally transmitted ACD were imported from the state of Pará. 324 Over the last 15 years an increase in autochthonous cases through this route has been 325 reported, making ACD an emerging disease [13]. Cutrim (2017) reported that there was a 326 significant increase in orally transmitted ACD from 2010 onwards [24]. The outbreak 327 described here was the largest in the state, which emphasized that the actions of the

328 public healthcare system must focus on promoting improvements in basic sanitation, in 329 addition to developing a safe food production program for the population. At the time of the 330 present study, there was no record of public policies that included safe production of these 331 products by the population.

332 Orally transmitted Chagas disease has particularities that are worth mentioning. In contrast 333 to vector-borne transmission, the higher parasite load after oral ingestion makes 334 controlling the disease more difficult for the immune system [25]. This is demonstrated 335 through higher parasitemia and increased tissue invasion [2]. It may lead to a shorter 336 incubation period, [26,27], early cardiac involvement and increased severity [28,29,30]. 337 However, the clinical manifestations may be nonspecific, which makes diagnosis a real 338 challenge for clinicians, given that ACD can be confused with other acute febrile illnesses, 339 such as leptospirosis, visceral leishmaniasis, malaria, enteric fever, rickettsiosis and some 340 arboviruses [10].

The possibility of orally acquired CD should always be suspected in situations in which an epidemiological link exists, such as in endemic areas or with more than one simultaneous case with ingestion of suspected food. A good clinical clue is the presence of fever for more than a week, associated with facial edema or bipalpebral edema and lymphadenopathy in patients with an epidemiological link. High frequency of fever and lymphadenopathy (90%) and low frequency of facial edema (38%) were found in the present study, which is in line with other reports [31,32,33].

The difficulty in establishing the diagnosis in real life was demonstrated here. The tools available that are recommended in the guidelines are low in efficiency, as they require several visits and involve complex and often rudimentary processes. The gold standard in diagnosing ACD is direct parasitological methods, but these have variable sensitivity, as

352 they are operator-dependent and need to be repeated on multiple samples [15, 34].353 Therefore, the best recommendation is to combine methods [15].

354 In infectious disease, identification of the agent is often the gold standard. In Chagas 355 disease, there are direct and indirect methods. Xenodiagnosis and blood culture are 356 among the indirect methods. Xenodiagnosis is an old but sophisticated procedure. It was 357 the first method used when CD was discovered. Laboratory-reared vectors are induced to 358 bite patients, and 30 to 60 days later, their excreta are analyzed to search for the parasite. 359 There are clearly some disadvantages in this technique, such as the time and resources 360 required to perform the procedure, as well as the risks associated with handling insect 361 vectors. Hemoculture is another indirect method, in which the examination should be 362 performed monthly for as long as six months. However, both xenodiagnosis and 363 hemoculture have low sensitivity [35,36] (around 20%) and are best suited for the chronic 364 phase of the disease [15,34].

365 The most sensitive of the direct parasitological methods consists of examination of fresh 366 blood in association with concentration methods [15,34,37] (Strout, buffy coat or 367 microhematocrit). However, considering that the region of the present study is endemic for 368 malaria, the blood smear technique is the tool that is most available, and it is easily 369 performed by some laboratory technicians in Maranhão. Furthermore, it is recommended 370 that the parasitological test should be repeated every 12-24 hours while the clinical 371 condition persists, until the parasite is found or another diagnosis is established [15,34,37]. 372 Unfortunately, due to the logistical difficulty in collecting samples in remote areas, it was 373 not possible to repeat this test in a timely manner. Also, there has been a shortage of 374 qualified technicians to perform good-quality microscopy over the years, thus posing a 375 threat to making diagnoses of ACD. In the present study, the peripheral blood smear

technique was used and positivity of 69.7% was found in a single-sample analysis, which
was higher than had been found in other reports [38]. Nonetheless, variable sensitivity has
been reported in the literature, with the best results found in reference laboratories
[31,39,40].

380 In diagnosing ACD, serological tests are considered to be the tool with the greatest 381 sensitivity [18] and specificity, through detecting IgG seroconversion or an IgG titer that 382 more than doubles over a minimum interval of 2 weeks. However, this is not the most 383 recommended tool, given the time required for achieving confirmation [34,37]. Moreover, 384 use of IgM has serious limitations in ACD: there are no commercial kits; positive controls 385 are hard to find; it remains positive for several years in chronic patients; and it might give 386 false positives with rheumatoid factor and in cases of other infectious diseases such as 387 leishmaniasis [37]. In the outbreak of the present report, two sequential serological tests 388 were performed, with an interval of 50 days between them. ELISA and IIF were used for 389 the first sample and ELISA and HAI for the subsequent sample. We found positivity of 390 66.6% (26/39) in the first sample and 17.7% seroconversion (6/35). Four samples were 391 lost in sequential analysis. The overall positivity of the serological tests was 91.4% (32/35). 392 This result was in line with those of several other publications [35,42,42]. It was not 393 possible to perform IgM, given that this is a complex technique and that it could present 394 false positive results, especially with leishmaniasis (an endemic disease in this region), 395 and the reference laboratory did not have the resources to do this test. If this test had been 396 performed, we could have found higher values, but with conflicting results.

397 Regarding the cure criteria, some remarks must be made. There are no gold standard 398 serological tests or biomarkers that define situations of CD cure. Molecular biology 399 analyses and non-conventional serological tests aimed at specific forms of *Trypanosoma*

400 like anti-live trypomastigote (FC-ALTA), anti-fixed epimastigote (FC-AFEA) and anti-three 401 evolutive forms (FC-ATE) or antigen tests (ELISA-F29) have been tested with inconclusive 402 results [43,44,45,46,47]. Therefore, reversion to negative seen through conventional 403 serological tests is considered to be the most reliable indicator of successful cure [48,49]. 404 and this is associated with the absence of parasitemia [50]. In long-term follow-up, after 54 405 months (4.5 years), we were able to perform serological tests (ELISA and IIF) on 26 406 individuals and found serological cure (negative tests) in 34.6% (9/26) and decreased IgG 407 titers in 15.3% (4/26). The other patients were lost to follow-up because they had changed 408 their place of residence to another state. These rates were lower than other reports on 409 ACD (up to 70% after 5 years) [50], considering that the total negativity or decline of 410 antibodies achieved 4.5 years after the outbreak was only 50%. This finding brings to light 411 the possibility of hypotheses such as pre-exposure or re-exposure to the pathogen. 412 Moreover, if additional samples had been obtained after shorter time intervals, this would 413 have enabled better analysis on the kinetics of antibodies. Nonetheless, it has previously 414 been noted that the decline in IgG titers can take many years, depending on the form of 415 infection [51,52].

416 Molecular diagnosis has restricted use, and is performed only by research centers or 417 reference laboratories, due to the lack of defined protocols and standardized operational 418 procedures, as well as the lack of commercial kits for use in routine surveillance. Despite 419 the diagnostic complexity of CD in all of its phases, we obtained excellent results using 420 conventional PCR to detect and identify T. cruzi in the clinical samples evaluated. These 421 specific primers were previously described in the literature by Wincker et al. (1994) [53] 422 and have been widely used as an adjunct to serological tests in diagnosing this disease. In 423 a recent meta-analysis, in which several molecular biology methods were compared,

Pascual-Vázquez et al. (2023) [54] demonstrated that it is not yet possible to determine the most effective molecular protocol because of the heterogeneity of the studies. In the present study, positivity was found through conventional PCR in 100% of the samples tested, even in patients whose other tests were all negative. This result is in line with reports on other outbreaks [55,56,57]. There is an urgent need, even without commercial platforms, for standardization of at least one molecular biology technique, so that this method can be used for routine diagnosis of ACD.

431 Genotyping is a powerful tool for investigating orally transmitted outbreaks of CD. T. cruzi 432 is divided into at least seven lineages, as discrete typing units (DTUs), from TcI to TcVI 433 and Tcbat (there is no consensus regarding the definition of the latter as a distinct DTU) 434 [58,59,60]. Velásquez-Ortiz et al. (2022) demonstrated that DTUs are widely distributed 435 across all countries, and in Brazil most cases are associated with Tcl [61]. However, it is 436 important to highlight that other genotypes have also been reported, like TcIII and TcIV 437 [57,62,63]. In northeastern Brazil, the most frequent forms are Tcl and TclV [64]. The 438 present study did not have the aim of analyzing the clonal aspect of T. cruzi strains. 439 However, construction of a phylogenetic tree containing 33 sequences from this outbreak 440 together with another 77 sequences extracted from another Brazilian outbreak from Pará 441 state showed a genetic similarity ranging from 94.8 to 100.0%, demonstrated that the 442 evolutionary distances are low and may represent a common source. Molecular studies 443 are needed in order to better evaluate the transmission dynamics or origin of these strains. 444 In the oral transmission route, the triatomine is accidentally macerated together with fruit or 445 food is directly contaminated by its feces when left unprotected. The species most 446 frequently involved in Colombia and Venezuela is *P. geniculatus*. In Brazil, greater 447 variability of species has been found, but most of them have belonged to the general

448 Triatoma and Panstrongylus [65]. Entomological surveillance is of great importance for 449 better understanding the life cycle and persistence of T. cruzi in nature. We distributed 450 PITs throughout the community and kept them there for six months. In this study, 27 viable 451 triatomines were found, of which more than 90% were Rhodnius pictipes, all in 452 peridomestic areas. No species were found inside houses. Previously, only two outbreaks 453 (in Brazil and Colombia) had reported this vector as probably involved in transmission 454 [66,67], but its ability to transmit the disease was recently demonstrated in an experimental 455 study [68]. The infection rate was 33.3%, which despite being higher than in most 456 surveillance in Brazil, was in line with findings from studies in other states, where rates 457 above 30% and up to 70% were found in peridomestic areas [69,70,71].

All the patients were treated with the only drug available in Brazil, benznidazole. This is a medication with a high rate of adverse reactions. Fortunately, suspension of the medication was only necessary due to adverse reactions in the cases of two patients, and both of these individuals received the treatment for 30 days, a period considered adequate. However, management of the treatment was quite arduous, given the need to use symptomatic medication in most patients. It is imperative that new initiatives, such as DNDi, are funded to develop new drugs or shorter therapeutic regimens.

The lethality of an outbreak is quite variable and can be influenced by four factors: the phenotype of the pathogen; the ingested parasite load; the individuals' susceptibility; and whether treatment was started early on. A recent meta-analysis demonstrated that the overall lethality of ACD is around 1%, but it also showed that lethality can reach up to 30% in large outbreaks (with more than 10 patients) [72]. It was not possible to analyze the first three factors mentioned above. Regarding early treatment, the mean length of time between symptom onset and treatment was 16.6 days (ranging from 6 to 54 days). This

472 demonstrates that action was implemented quickly by the surveillance center, which may473 have had an impact on the absence of lethal outcomes.

474 Most orally transmitted ACD cases have occurred after ingestion of fresh juices, like acaí 475 (Euterpe oleracea) and sugar cane (Saccharum spp.). However, other beverages have 476 also been cited [72]. In this event, the most probable source was bacaba juice. This was 477 the first time that this fruit had been reported to be involved in an outbreak in the state of 478 Maranhão, but reports of this in Venezuela and another Brazilian state have already been 479 published [63,73]. At first sight, it may seem that this is a problem restricted to remote and 480 highly vulnerable locations, but a study demonstrated the presence of T. cruzi in acai 481 products sold in markets in Rio de Janeiro, Brazil, which is well outside the Amazon region 482 [74]. Furthermore, from the perspective of the "One Health approach", with intense human 483 migration and exporting of natural products from endemic areas, CD can already be 484 considered to be a global health problem: papers published in European and North 485 American countries have demonstrated this concern [75]. It is also important to mention a 486 study that demonstrated the presence of infected triatomines in a densely populated area 487 in the northeastern region of the United State, a non-endemic area [76]. Therefore, there is 488 an urgent need to implement safe food production programs, aligned with better diagnostic 489 and therapeutic tools.

After this outbreak, a series of training sessions were conducted among the municipality's healthcare team and communities, with the aim of raising awareness of the importance of Chagas disease. Given that the foods involved in its transmission are the only source of survival for most people in the region, stopping eating them is not an option. The population was trained to produce this food in a safer way, while maintaining the artisanal process, but this did not constitute a guidance policy extended to the entire state.

This event demonstrates that there is still a long way to go before this disease is controlled. As mentioned previously, the status of CD as a neglected tropical disease means that controlling or eradicating it through applying public health strategies remains possible. Despite the contemporary nature of the difficulties described here, they remain very similar to those at the time of its discovery. Even after more than a century, Carlos Chagas is still right when he said:

502 "Will it be possible, within public hygiene, to find efficacious ways of
503 attenuating this affliction? We believe so, if this problem—most surely
504 a problem of the State and of humanity—becomes the concern of a
505 scientifically well-advised statesman." (Chagas, 1917).

506 As globalization breaks all borders through the migration of people and the exporting of 507 raw materials, we postulate here that we must spread Carlos Chagas' thoughts throughout 508 the world.

509

510 **5. Conclusions**

511 Chagas disease is a classic NTD with a special characteristic: it is called "the silent 512 disease". The ability of this disease to keep the host virtually asymptomatic for a long time 513 allows it to thrive. In this study, we present all the barriers encountered in managing real-514 life situations of an acute event: the vulnerability of the population; the dependence on old 515 diagnostic techniques, together with little interest in developing microscopy professionals; 516 lack of standardization of molecular biology techniques; and few therapeutic options, with 517 many side effects. We demonstrated that rapid surveillance action with early initiation of 518 treatment culminated in an outbreak without deaths. To improve early treatment, it is 519 necessary to invest in better diagnostic techniques and make them widely available. We

520 also demonstrated and propose that polymerase chain reaction should be standardized 521 within the diagnostic routine. Acute Chagas disease is a threat to public health. While 522 advances in vector control have been achieved, the peridomestic and sylvatic cycle 523 remains active, thus perpetuating the parasite in nature. The most vulnerable populations 524 continue to be those in extreme poverty, without access to basic sanitation, or who live 525 near the Amazon rainforest. However, as the beverages that are classically involved in 526 oral transmission are increasingly exported to other regions, and with the intense human 527 migration that has been occurring increasingly, outbreaks in non-endemic regions are an 528 additional concern in relation to controlling CD. Until everyone looks at the problem from a 529 "One Health" perspective, no nation is safe from Chagas disease.

530

531 Acknowledgements

532 The authors thank the State Health Department of Maranhão (SES/MA) and the Oswaldo 533 Cruz Institute - Central Public Health Laboratory of Maranhão (IOC-LACEN/MA) for their 534 logistical support and analyses on laboratory tests. The authors also thank the Foundation 535 for Support of Scientific Research and Technological Development of Maranhão 536 (FAPEMA) and the National Council for Scientific and Technological Development (CNPq). 537

538 References

539

540 1. Lidani KCF, Andrade FA, Bavia L, et al. Chagas Disease: From Discovery to a

- 541 Worldwide Health Problem. *Front Public Health*. 2019;7:166. Published 2019 Jul 2.
- 542 doi:10.3389/fpubh.2019.00166

- 543 2. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375(9723):1388-
- 544 1402. doi:10.1016/S0140-6736(10)60061-X
- 545 3. Malecela MN, Ducker C. A road map for neglected tropical diseases 2021-2030. Trans
- 546 *R* Soc Trop Med Hyg. 2021;115(2):121-123. doi:10.1093/trstmh/trab002
- 547 4. Chagas C 1908. Trypanosoma minasense: Nota preliminar. Brasil Médico 22: 471.
- 548 5. Chagas C 1909 c. Nova espécie mórbida do homem, produzida por um Trypanozoma
- 549 (Trypanozoma cruzi): Nota prévia. Brasil Médico 23: 161.
- 550 6. Chagas C 1909 d. Nova tripanossomíase humana: Estudos sobre a morfologia e o
- 551 ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., agente etiológico de nova
- 552 entidade mórbida do homem. Memórias do Instituto Oswaldo Cruz 1: 159-218.
- 553 7. Chagas C 1910 a. Aspecto clínico geral da nova entidade mórbida produzida pelo
- 554 Schizotrypanum cruzi: Nota prévia. Brasil Médico 24: 263-265
- 555 8. Gómez-Ochoa SA, Rojas LZ, Echeverría LE, Muka T, Franco OH. Global, Regional,
- and National Trends of Chagas Disease from 1990 to 2019: Comprehensive Analysis
- of the Global Burden of Disease Study. *Glob Heart*. 2022;17(1):59. Published 2022
- 558 Aug 24. doi:10.5334/gh.1150
- 9. Martins-Melo FR, Castro MC, Werneck GL. Levels and trends in Chagas disease-
- 560 related mortality in Brazil, 2000-2019. *Acta Trop.* 2021;220:105948.
- 561 doi:10.1016/j.actatropica.2021.105948
- 562 10. Franco-Paredes C, Villamil-Gómez WE, Schultz J, et al. A deadly feast: Elucidating the
- 563 burden of orally acquired acute Chagas disease in Latin America Public health and
- travel medicine importance. *Travel Med Infect Dis.* 2020;36:101565.
- 565 doi:10.1016/j.tmaid.2020.101565

- 566 11. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375(9723):1388-
- 567 1402. doi:10.1016/S0140-6736(10)60061-X
- 568 12. Pérez-Molina JA, Molina I. Chagas disease. *Lancet.* 2018;391(10115):82-94.
- 569 doi:10.1016/S0140-6736(17)31612-4
- 570 13. Brazil, Ministry of Health. Notifiable Diseases Information System Sinan Net; 2024
- 571 [cited 2024 Apr 5th]. [Internet]. Available from:
- 572 http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sinannet/cnv/chagasbr.def
- 573 14. Pan American Health Organization. 49th Directing Council, 61th session of the regional
- 574 committee of WHO for the Americas. Washington, D.C.: PAHO; 2009. [Internet].
- 575 Available from: <u>https://iris.paho.org/handle/10665.2/20</u>
- 576 15. Pan American Health Organization. Guidelines for the diagnosis and treatment of
- 577 Chagas disease. Washington, D.C.: PAHO; 2019. [Internet]. Available from:
- 578 https://www.who.int/publications/i/item/9789275120439
- 579 16. Egüez KE, Alonso-Padilla J, Terán C, et al. Rapid diagnostic tests duo as alternative to
- 580 conventional serological assays for conclusive Chagas disease diagnosis. *PLoS Negl*
- 581 *Trop Dis.* 2017;11(4):e0005501. Published 2017 Apr 3.
- 582 doi:10.1371/journal.pntd.0005501
- 583 17. Rivero R, Santini MS, Lopez-Albizu C, et al. Comparative evaluation of four rapid
- 584 diagnostic tests that detect human Trypanosoma cruzi-specific antibodies to support
- 585 diagnosis of Chagas Disease in urban population of Argentina. *PLoS Negl Trop Dis*.
- 586 2024;18(3):e0011997. Published 2024 Mar 15. doi:10.1371/journal.pntd.0011997
- 587 18. Candia-Puma MA, Machaca-Luque LY, Roque-Pumahuanca BM, et al. Accuracy of
- 588 Diagnostic Tests for the Detection of Chagas Disease: A Systematic Review and Meta-

- 589 Analysis. *Diagnostics (Basel)*. 2022;12(11):2752. Published 2022 Nov 10.
- 590 doi:10.3390/diagnostics12112752
- 591 19. Molina I, Salvador F, Sánchez-Montalvá A, et al. Toxic Profile of Benznidazole in
- 592 Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product
- from Two Different Manufacturers. Antimicrob Agents Chemother. 2015;59(10):6125-
- 594 6131. doi:10.1128/AAC.04660-14
- 595 20. Lascano F, García Bournissen F, Altcheh J. Review of pharmacological options for the
- treatment of Chagas disease. *Br J Clin Pharmacol.* 2022;88(2):383-402.
- 597 doi:10.1111/bcp.14700
- 598 21. González S, Wall RJ, Thomas J, et al. Short-course combination treatment for
- 599 experimental chronic Chagas disease. *Sci Transl Med.* 2023;15(726):eadg8105.
- 600 doi:10.1126/scitranslmed.adg8105
- 601 22. Cafferata ML, Toscani MA, Althabe F, et al. Short-course Benznidazole treatment to
- 602 reduce Trypanosoma cruzi parasitic load in women of reproductive age (BETTY): a
- 603 non-inferiority randomized controlled trial study protocol. *Reprod Health*.
- 604 2020;17(1):128. Published 2020 Aug 24. doi:10.1186/s12978-020-00972-1
- 605 23. IBGE INSTITUTO BRASILEIRO DE GEOGRAFIA E ESTATÍSTICA. Censo Brasileiro
- de 2022; Rio de Janeiro: IBGE, 2022. [cited 2024 Apr 15]. [Internet]. Available from:
- 607 <u>https://cidades.ibge.gov.br/brasil/ma/panorama</u>
- 608 24. Cutrim FSRF. Estudo dos casos agudos de doença de Chagas no Maranhão, Brasil, e
- 609 sua relação com a pobreza. Rio de Janeiro, 2017. PhD Thesis, Instituto Oswaldo Cruz.
- 610 2017. Available from: <u>https://www.arca.fiocruz.br/handle/icict/49474</u>
- 611 25. Silva-Dos-Santos D, Barreto-de-Albuquerque J, Guerra B, et al. Unraveling Chagas
- 612 disease transmission through the oral route: Gateways to Trypanosoma cruzi infection

- and target tissues. *PLoS Negl Trop Dis.* 2017;11(4):e0005507. Published 2017 Apr 5.
- 614 doi:10.1371/journal.pntd.0005507
- 615 26. Pinto AY, Valente SA, Valente Vda C, Ferreira Junior AG, Coura JR. Fase aguda da
- 616 doença de Chagas na Amazônia brasileira: estudo de 233 casos do Pará, Amapá e
- 617 Maranhão observados entre 1988 e 2005 [Acute phase of Chagas disease in the
- 618 Brazilian Amazon region: study of 233 cases from Pará, Amapá and Maranhão
- 619 observed between 1988 and 2005]. *Rev Soc Bras Med Trop.* 2008;41(6):602-614.
- 620 doi:10.1590/s0037-86822008000600011
- 621 27. Nóbrega AA, Garcia MH, Tatto E, et al. Oral transmission of Chagas disease by
- 622 consumption of açaí palm fruit, Brazil. *Emerg Infect Dis.* 2009;15(4):653-655.
- 623 doi:10.3201/eid1504.081450
- 624 28. Coura JR, Viñas PA. Chagas disease: a new worldwide challenge. Nature.
- 625 2010;465(7301):S6-S7. doi:10.1038/nature09221
- 626 29. Noya BA, Díaz-Bello Z, Colmenares C, et al. Update on oral Chagas disease outbreaks
- 627 in Venezuela: epidemiological, clinical and diagnostic approaches. *Mem Inst Oswaldo*
- 628 *Cruz.* 2015;110(3):377-386. doi:10.1590/0074-02760140285
- 629 30. Shikanai-Yasuda MA, Carvalho NB. Oral transmission of Chagas disease. Clin Infect
- 630 Dis. 2012;54(6):845-852. doi:10.1093/cid/cir956
- 631 31. Shikanai-Yasuda MA, Marcondes CB, Guedes LA, et al. Possible oral transmission of
- 632 acute Chagas' disease in Brazil. *Rev Inst Med Trop Sao Paulo*. 1991;33(5):351-357.
- 633 doi:10.1590/s0036-46651991000500003
- 634 32. Bastos CJ, Aras R, Mota G, et al. Clinical outcomes of thirteen patients with acute
- 635 chagas disease acquired through oral transmission from two urban outbreaks in

- 636 northeastern Brazil. *PLoS Negl Trop Dis.* 2010;4(6):e711. Published 2010 Jun 15.
- 637 doi:10.1371/journal.pntd.0000711
- 638 33. Vargas A, Malta JMAS, Costa VMD, et al. Investigação de surto de doença de Chagas
- 639 aguda na região extra-amazônica, Rio Grande do Norte, Brasil, 2016 [Investigation of
- an outbreak of acute Chagas disease outside the Amazon Region, in Rio Grande do
- 641 Norte State, Brazil, 2016]. *Cad Saude Publica*. 2018;34(1):e00006517. Published 2018
- 642 Feb 5. doi:10.1590/0102-311X00006517
- 643 34. Brazil, Ministry of Health. Health Surveillance Guide: vol 2; 6. Ed, Brasília, Health
- 644 Ministry, 2023 [Internet]. Available from: <u>https://www.gov.br/saude/pt-br/centrais-de-</u>
- 645 <u>conteudo/publicacoes/svsa/vigilancia/guia-de-vigilancia-em-saude-volume-2-6a-</u>
- 646 <u>edicao/view</u>
- 647 35. Schijman AG, Alonso-Padilla J, Longhi SA, Picado A. Parasitological, serological and
- 648 molecular diagnosis of acute and chronic Chagas disease: from field to
- laboratory. *Mem Inst Oswaldo Cruz*. 2022;117:e200444. Published 2022 May 23.
- 650 doi:10.1590/0074-02760200444
- 651 36. de Castro AM, Luquetti AO, Rassi A, Chiari E, Galvão LM. Detection of parasitemia
- 652 profiles by blood culture after treatment of human chronic Trypanosoma cruzi
- 653 infection. *Parasitol Res.* 2006;99(4):379-383. doi:10.1007/s00436-006-0172-5
- 654 37. de Sousa AS, Vermeij D, Ramos AN Jr, Luquetti AO. Chagas disease. Lancet.
- 655 2024;403(10422):203-218. doi:10.1016/S0140-6736(23)01787-7
- 656 38. Noya BA, Díaz-Bello Z, Colmenares C, et al. The performance of laboratory tests in the
- 657 management of a large outbreak of orally transmitted Chagas disease. *Mem Inst*
- 658 Oswaldo Cruz. 2012;107(7):893-898. doi:10.1590/s0074-02762012000700009

- 659 39. Pinto AYN, Farias JR, Marcal AS, Galucio AL, Costi RR, Valente VC, Valente SAS.
- 660 Doença de Chagas Aguda grave autóctone na Amazônia brasileira. Revista Paraense
- 661 de Medicina 2007; 21:7–12.
- 662 40. Steindel M, Kramer Pacheco L, Scholl D, et al. Characterization of Trypanosoma cruzi
- 663 isolated from humans, vectors, and animal reservoirs following an outbreak of acute
- human Chagas disease in Santa Catarina State, Brazil. *Diagn Microbiol Infect Dis*.
- 665 2008;60(1):25-32. doi:10.1016/j.diagmicrobio.2007.07.016
- 666 41. Suárez C, Nolder D, García-Mingo A, Moore DAJ, Chiodini PL. Diagnosis and Clinical
- 667 Management of Chagas Disease: An Increasing Challenge in Non-Endemic Areas. Res
- 668 Rep Trop Med. 2022;13:25-40. Published 2022 Jul 22. doi:10.2147/RRTM.S278135
- 669 42. Gabaldón-Figueira JC, Skjefte M, Longhi S, et al. Practical diagnostic algorithms for
- 670 Chagas disease: a focus on low resource settings. *Expert Rev Anti Infect Ther.*
- 671 2023;21(12):1287-1299. doi:10.1080/14787210.2023.2279110
- 43. Krettli AU, Brener Z. Resistance against Trypanosoma cruzi associated to anti-living

673 trypomastigote antibodies. *J Immunol*. 1982;128(5):2009-2012.

- 44. Galvao LM, Nunes RM, Cançado JR, Brener Z, Krettli AU. Lytic antibody titre as a
- 675 means of assessing cure after treatment of Chagas disease: a 10 years follow-up
- 676 study. Trans R Soc Trop Med Hyg. 1993;87(2):220-223. doi:10.1016/0035-
- 677 9203(93)90501-g
- 45. Martins-Filho OA, Eloi-Santos SM, Teixeira Carvalho A, et al. Double-blind study to
- 679 evaluate flow cytometry analysis of anti-live trypomastigote antibodies for monitoring
- treatment efficacy in cases of human Chagas' disease. *Clin Diagn Lab Immunol.*
- 681 2002;9(5):1107-1113. doi:10.1128/cdli.9.5.1107-1113.2002

- 46. Wendling AP, Vitelli-Avelar DM, Sathler-Avelar R, et al. The use of IgG antibodies in
- 683 conventional and non-conventional immunodiagnostic tests for early prognosis after
- treatment of Chagas disease. *J Immunol Methods*. 2011;370(1-2):24-34.
- 685 doi:10.1016/j.jim.2011.05.003
- 47. Fabbro D, Velazquez E, Bizai ML, et al. Evaluation of the ELISA-F29 test as an early
- 687 marker of therapeutic efficacy in adults with chronic Chagas disease. *Rev Inst Med*
- 688 Trop Sao Paulo. 2013;55(3):S0036-46652013000300167. doi:10.1590/S0036-
- 689 46652013000300005
- 48. de Lana M, Martins-Filho OA. Revisiting the Posttherapeutic Cure Criterion in Chagas
- Disease: Time for New Methods, More Questions, Doubts, and Polemics or Time to
- 692 Change Old Concepts?. *Biomed Res Int*. 2015;2015:652985. doi:10.1155/2015/652985
- 49. Moreira CHV, Bierrenbach AL, Taconeli CA, de Oliveira-da Silva LC, Buss LF, Keating
- 694 SM, Manuli ER, Carvalho NB, Guastini C, Coco SB, Lindoso JA[^] L, Franco LAM,
- 695 Ghilardi F, Sales FCdS, Contestable P, Di Germanio C, Busch MP and Sabino EC
- 696 (2023) Parasitemia and antibody response to benznidazole treatment in a cohort of
- 697 patients with chronic Chagas disease. Front. Parasitol. 2:1235925. doi:
- 698 10.3389/fpara.2023.1235925
- 50. Buss LF, Campos de Oliveira-da Silva L, Moreira CHV, et al. Declining antibody levels
- to Trypanosoma cruzi correlate with polymerase chain reaction positivity and
- 701 electrocardiographic changes in a retrospective cohort of untreated Brazilian blood
- donors. *PLoS Negl Trop Dis.* 2020;14(10):e0008787. Published 2020 Oct 27.
- 703 doi:10.1371/journal.pntd.0008787

- 51. Rodriques Coura J, de Castro SL. A critical review on Chagas disease
- 705 chemotherapy. Mem Inst Oswaldo Cruz. 2002;97(1):3-24. doi:10.1590/s0074-
- 706 02762002000100001
- 52. Cancado JR. Long term evaluation of etiological treatment of chagas disease with
- benznidazole. *Rev Inst Med Trop Sao Paulo*. 2002;44(1):29-37.
- 53. Wincker P, Britto C, Pereira JB, Cardoso MA, Oelemann W, Morel CM. Use of a
- 710 simplified polymerase chain reaction procedure to detect Trypanosoma cruzi in blood
- samples from chronic chagasic patients in a rural endemic area. *Am J Trop Med Hyg.*
- 712 1994;51(6):771-777. doi:10.4269/ajtmh.1994.51.771
- 713 54. Pascual-Vázquez G, Alonso-Sardón M, Rodríguez-Alonso B, et al. Molecular diagnosis
- of Chagas disease: a systematic review and meta-analysis. *Infect Dis Poverty*.
- 715 2023;12(1):95. Published 2023 Oct 16. doi:10.1186/s40249-023-01143-7
- 716 55. Hernández C, Cucunubá Z, Flórez C, et al. Molecular Diagnosis of Chagas Disease in
- 717 Colombia: Parasitic Loads and Discrete Typing Units in Patients from Acute and
- 718 Chronic Phases [published correction appears in PLoS Negl Trop Dis. 2016 Oct 28;10
- 719 (10):e0005112]. *PLoS Negl Trop Dis.* 2016;10(9):e0004997. Published 2016 Sep 20.
- 720 doi:10.1371/journal.pntd.0004997
- 56. Souza-Lima Rde C, Barbosa Md, Coura JR, et al. Outbreak of acute Chagas disease
- associated with oral transmission in the Rio Negro region, Brazilian Amazon. *Rev Soc*
- 723 Bras Med Trop. 2013;46(4):510-514. doi:10.1590/0037-8682-1367-2013
- 57. Santana RAG, Guerra MGVB, Sousa DR, et al. Oral Transmission of Trypanosoma
- ruzi, Brazilian Amazon. *Emerg Infect Dis.* 2019;25(1):132-135.
- 726 doi:10.3201/eid2501.180646

- 58. Zingales B, Miles MA, Campbell DA, et al. The revised Trypanosoma cruzi subspecific
- nomenclature: rationale, epidemiological relevance and research applications. *Infect*
- 729 Genet Evol. 2012;12(2):240-253. doi:10.1016/j.meegid.2011.12.009
- 730 59. Lima L, Espinosa-Álvarez O, Ortiz PA, et al. Genetic diversity of Trypanosoma cruzi in
- bats, and multilocus phylogenetic and phylogeographical analyses supporting Tcbat as
- an independent DTU (discrete typing unit). *Acta Trop.* 2015;151:166-177.
- 733 doi:10.1016/j.actatropica.2015.07.015
- 60. Zingales B, Macedo AM. Fifteen Years after the Definition of *Trypanosoma cruzi* DTUs:
- 735 What Have We Learned?. *Life (Basel)*. 2023;13(12):2339. Published 2023 Dec 14.
- 736 doi:10.3390/life13122339
- 737 61. Velásquez-Ortiz N, Herrera G, Hernández C, Muñoz M, Ramírez JD. Discrete typing
- 738 units of Trypanosoma cruzi: Geographical and biological distribution in the
- 739 Americas. Sci Data. 2022;9(1):360. Published 2022 Jun 24. doi:10.1038/s41597-022-
- 740 01452-w
- 741 62. Monteiro WM, Magalhães LK, Santana Filho FS, Borborema M, Silveira H, Barbosa
- 742 Md. Trypanosoma cruzi TcIII/Z3 genotype as agent of an outbreak of Chagas disease
- in the Brazilian Western Amazonia. *Trop Med Int Health*. 2010;15(9):1049-1051.
- 744 doi:10.1111/j.1365-3156.2010.02577.x
- 63. Esper HR, Freitas VLT, Assy JGPL, et al. Fatal evolution of acute Chagas disease in a
- child from Northern Brazil: factors that determine poor prognosis. *Rev Inst Med Trop*
- 747 Sao Paulo. 2019;61:e27. doi:10.1590/S1678-9946201961027
- 64. Freitas VLT, Piotto MR, Esper HR, et al. Detection of Trypanosoma cruzi DTUs Tcl and
- 749 TcIV in two outbreaks of orally-transmitted Chagas disease in the Northern region of

- 750 Brazil. *Rev Inst Med Trop Sao Paulo*. 2023;65:e7. Published 2023 Jan 16.
- 751 doi:10.1590/S1678-9946202365007
- 752 65. López-García A, Gilabert JA. Oral transmission of Chagas disease from a One Health
- approach: A systematic review. *Trop Med Int Health*. 2023;28(9):689-698.
- 754 doi:10.1111/tmi.13915
- 66. Valente SA, da Costa Valente V, das Neves Pinto AY, et al. Analysis of an acute
- 756 Chagas disease outbreak in the Brazilian Amazon: human cases, triatomines, reservoir
- mammals and parasites. *Trans R Soc Trop Med Hyg.* 2009;103(3):291-297.
- 758 doi:10.1016/j.trstmh.2008.10.047
- 759 67. Hernández C, Vera MJ, Cucunubá Z, et al. High-Resolution Molecular Typing of
- 760 Trypanosoma cruzi in 2 Large Outbreaks of Acute Chagas Disease in Colombia. J
- 761 Infect Dis. 2016;214(8):1252-1255. doi:10.1093/infdis/jiw360
- 762 68. de Abreu AP, Lucas da Silva HF, Sarto MPM, et al. Infection susceptibility and vector
- competence of Rhodnius robustus Larrousse, 1927 and R. pictipes Stal, 1872
- 764 (Hemiptera, Reduviidae, Triatominae) for strains of Trypanosoma cruzi (Chagas, 1909)
- 765 (Kinetoplastida, Trypanosomatidae) I, II and IV. *Parasit Vectors*. 2022;15(1):239.
- 766 Published 2022 Jun 30. doi:10.1186/s13071-022-05350-3
- 767 69. Barbosa-Silva AN, Câmara AC, Martins K, et al. Characteristics of Triatomine
- infestation and natural Trypanosoma cruzi infection in the State of Rio Grande do
- 769 Norte, Brazil. *Rev Soc Bras Med Trop.* 2016;49(1):57-67. doi:10.1590/0037-8682-
- 770 0300-2015
- 771 70. Barbosa-Silva AN, Souza RCM, Diotaiuti L, et al. Synanthropic triatomines (Hemiptera:
- Reduviidae): infestation, colonization, and natural infection by trypanosomatids in the

- 573 State of Rio Grande do Norte, Brazil. *Rev Soc Bras Med Trop.* 2019;52:e20190061.
- 774 Published 2019 Jul 18. doi:10.1590/0037-8682-0061-2019
- 775 71. Paixão DDS, Portela Madeira F, Costa de Jesus A, et al. Mapping the Silent Threat: A
- 776 Comprehensive Analysis of Chagas Disease Occurrence in Riverside Communities in
- the Western Amazon. *Pathogens*. 2024;13(2):176. Published 2024 Feb 15.
- 778 doi:10.3390/pathogens13020176
- 779 72. Bruneto EG, Fernandes-Silva MM, Toledo-Cornell C, et al. Case-fatality From Orally-
- 780 transmitted Acute Chagas Disease: A Systematic Review and Meta-analysis. Clin
- 781 Infect Dis. 2021;72(6):1084-1092. doi:10.1093/cid/ciaa1148
- 782 73. Benitez JA, Araujo B, Contreras K, et al. Urban outbreak of acute orally acquired
- 783 Chagas disease in Táchira, Venezuela. *J Infect Dev Ctries*. 2013;7(8):638-641.
- 784 Published 2013 Aug 15. doi:10.3855/jidc.3620
- 785 74. Ferreira RTB, Cabral ML, Martins RS, et al. Detection and genotyping of Trypanosoma
- 786 cruzi from açai products commercialized in Rio de Janeiro and Pará, Brazil. Parasit
- 787 *Vectors*. 2018;11(1):233. Published 2018 Apr 10. doi:10.1186/s13071-018-2699-6
- 788 75. Gonzalez-Sanz M, Crespillo-Andújar C, Chamorro-Tojeiro S, Monge-Maillo B, Perez-
- 789 Molina JA, Norman FF. Chagas Disease in Europe. *Trop Med Infect Dis*.
- 790 2023;8(12):513. Published 2023 Dec 1. doi:10.3390/tropicalmed8120513
- 791 76. Peterson JK, Hoyos J, Bartlett CR, et al. First Report of Chagas Disease Vector
- 792 Species Triatoma sanguisuga (Hemiptera: Reduviidae) Infected with Trypanosoma
- cruzi in Delaware. *Am J Trop Med Hyg*. Published online March 26, 2024.
- 794 doi:10.4269/ajtmh.23-0915
- 795
- 796 Supporting information

797

798 Methodology of Polymerase Chain Reaction

799 Extraction of the parasite's genetic material from blood samples and amplification 800 by PCR: for the DNA extraction process from blood samples, the commercial QIAamp 801 DNA Blood kit (QIAGEN® GmbH, Hilden, Germany), were used, according to the 802 manufacturer's instructions. The DNA obtained were quantified in Nanodrop (ND1000® -803 Thermo Fisher Scientific, Waltham, MA) and stored at -20°C until use. For each PCR 804 reaction, 25 µl of the reaction kit mix containing 0.2 mM of each of the dNTPs, 2 mM 805 MgSO4, 1 × high-fidelity Tag buffer 10X PCR Gold Buffer, 1 U were added to a PCR tube 806 of Platinum Tag DNA polymerase (Life Technologies®, Carlsbad CA) and 0.6 µM of each 807 primer specific for the kinetoplast minicircle region (kDNA) of T. cruzi and previously 808 described (WINCKER by et al., 1994), primer Forward Tc121 809 5'AAATAATGTACGGGKGAGATGCATGA-3' Tc122 5'and Reverse 810 GGTTCGATTGGGGTTGGTGTAATATA-3', and 1 µL of template DNA. The final volume 811 was completed to 50 µL with RNase and DNase free water. The thermal amplification 812 cycle began with 2 min of activation at 95 °C, followed by 35 cycles of 95 °C for 40s, 63.5 °C for 1 minute, 72 °C for 1 min, and a final extension cycle at 72 °C for 5 min. 813

Analysis of PCR amplified products: to verify the efficiency of the PCR assays and
determine the size of the amplified DNA fragment, around 8 μL of the PCR product plus 2
μL of sample buffer (Blue/Orange 6X Loading Dye) was applied to a 2% agarose gel
(Promega®, USA) of boric acid at 100 V for 1 hour (MANIATIS; SAMBROOK et al., 1989).
After electrophoresis, the gels were stained with Gel Red from Biotium® (1:1000) for 20
minutes and observed on an ultraviolet transilluminator. To determine the size of the PCR

820 products, a 100bp DNA ladder molecular size marker (INVITROGEN®, Life Technologies,

USA) was included in each run.

822 Purification of PCR products and sequencing: purification of the PCR product of the 823 specific 330bp fragment was done using the Wizard® SV Gel and PCR Clean-Up System 824 (PROMEGA®) kit according to the manufacturer's instructions. To verify purity, the 825 integrity and concentration of the purified product were checked in nanodrop. Sequencing 826 of the purified PCR product was carried out using the dideoxynucleotide chain termination 827 method of Sanger et al. (1977). Each DNA strand will be sequenced in both directions of 828 the double strand (positive sense and negative sense) with the "ABI Prism BigDye Kit®" on 829 the automatic sequencer ABI 3130 Genétic Analyzer (Applied Biosystems®). Samples 830 were sequenced at least twice in each direction of the strand, making a total of four 831 sequences from the same sample. All sequencing were carried out by the company 832 Myleus Biotecnologia Ltda®, based in Belo Horizonte-MG.

833 **Computational analysis of sequences:** to check the quality of the sequences, the 834 electropherograms obtained during the sequencing process were analyzed using the 835 ChromasPro ® data program (Technelysium Pty Ltd®). The similarity between the 836 nucleotide sequences obtained was verified by the BLASTn program from the BLAST 2.0® 837 package (Basic Alignment Search Tool (ALTSCHUL et al., 1997), from where The T. cruzi 838 reference sequences from Genbank were also selected for comparative analyzes through 839 alignment using the MEGA® version 4.0 program (TAMURA et al., 2013) and construction 840 of a phylogenetic tree.

841

S1 Figure 1. Phylogenetic tree of the 33 samples from the outbreak along with 77
samples from another outbreak

> HG008276.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patent 049 clone PA412 HG008275.1 Hom o sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patent 049 clone PA411 iG008433.1 Hom o sapiens genomic DNA containing Trypanosoma cruzikinetoplast minicircle DNA family C patient 078 clone PA607 16008280.1 Hom o sapiens genomic DNA comaining Trypanosoma cruzi kinetoplast minicircle DNA family B patent 050 clone PA418 16008194.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patient 025 clone PA473 HG008447.1 Hom o sapiens genomic DNA containing Trypanosom a cruzi kinetoplast minicircle DNA family C patient080 clone PA821 HG008212.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patient 032 clone PA497 HG008261.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patient 046 clone PA461 HG008277.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinezoplast minicircle DNA family B patient 049 clone PA413 - HG008169.1 Hom o septens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patent 016 clone PA224 HG008435.1 Homo septens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patent 078 clone PA609 08410.1 Homo sapiens genomic DNA con aiming Trypanosoma cruzi kinemplast minicircle DNA family C papent 075 clone PA587 HG008282.1 Hom o sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patient 050 clone PA425 HG008278.1 Homo septens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patient 049 clone PA414 -HG008319.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 061 clone PA673 HG008492.1 Hom o septens genomic DNA containing Trypanosom a cruzi kinetoplast minicircle DNA family C patient 087 clone PA670 HG008442.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinemoplast minicircle DNA family C patient 080 clone PA620 - HG008472.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 084 clone PA794 HG008445.1 Hom o saplens genomic DNA containing Tripanosom a cruzi kine polast minicircle DNA family C papent 080 clone PA624 HG008393.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinemoplast minicircle DNA family C patient 073 clone PA575 HG008231.1 Homo septens genomic DNA conteining Trypanosoma cruzi kinetoplast minicircle DNA femily B patent 038 clone PA28 HG008315.1 Homo septens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 060 clone PA522 - HG008443.1 Hom o sapiens genomic DNA containing Trypanosom a cruzi kinetoplast minicircle DNA family C patient 080 clone PA622 HG008205.1 Hom o sapiens genomic DNA containing Trypan osoma cruzi kinetoplast minicircle DNA family B patient 028 clone PA503 HG008230.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patient 038 clone PA296 HG008208.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patent 028 clone PA504 -HG008441.1 Hom o sapiens genomic DNA containing Trypanosom a cruzi kinetoplast minicircle DNA family C patient 079 clone PA617 — HG008432.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplascminicircle DNA family С рацент 078 clone РА806 HG008438.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 079 clone PA614 FM 207199.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA patient 1491 34 clone 170E FM 207196.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA patient 1491 34 clone 167E - HG 008425.1 Hom o sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 077 clone PA701 HG008273.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patent 049 clone PA409 HG008469.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patent 083 clone PA655 HG008232.1 Hom o sapiens genomic DNA comaining Trypanosoma cruzi kinetoplast minicircle DNA family B patent 038 clone PA298 – HG008471.1 Homo sapiens genomic DNA containing Trypanosoma cruzi k inexoplast minicircle DNA family C patient 083 clone PA657 HG008457.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 081 clone PA838 HG008454.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 081 clone PA835 HG008272.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinemplast minicircle DNA family B patient 049 clone PA407 HG008434.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetopias; minicircle DNA family C patient 078 clone PA608 HG008439.1 Hom o sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 079 clone PA615 HG008458.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 081 clone PA640 HG008168.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patient 016 clone PA220 - HG008470.1 Hom o septens genomic DNA containing Trypanosom a cruzi kinetoplast minicircle DNA family C patient 083 clone PA656 HG008377.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 071 clone PA585 HG008392.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 073 clone PA574 0N037212.1 Trypan osoma cruzi strain PRM A77 minicircle kinetoplast complete sequence HG008436.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 078 clone PA610 DN037209.1 Trypanosoma cruzi strain PRM A72 minicircle kinetoplast complete sequence HG008440.1 Homo saprens genomic DNA comaining Trypanosoma cruzi kinecoplasi minicircle DNA family C pavenc019 clone PA616 HG008209.1 Hom o sapiens genomic DNA containing Trypanosom a cruzi kinetoplast minicircle DNA family. B patient 031 clone PA327 t HG008281.1 Homo septens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patent 050 clone PA420 HG008419.1 Hom o saplens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patent 076 clone PA597 ON037211.1 Trypanosoma cruzi strain PRM A74 minicircle kinetoplast complete sequence - HG008354.1 Hom o septens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patent 067 clone PA545 ON037228 1 Trypanosoma cruzi strain PRM 4120 minicircle kinetoplast complete sequence HG008446.1 Hom o sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 080 clone PA625 HG008320.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinemoplast minicircle DNA family C patient 061 clone PA674 u HG008456.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 081 clone PA637 HG008274.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinemoplast minicircle DNA family B patient 049 clone PA410 HG008341.1 Hom o sapiens genomic DNA containing Trypanosom a cruzi kinetoplast minicircle DNA family C patient 064 clone PA712 HG008455.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetopiast minicircle DNA family C patient 081 clone PA636 HG008371.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patent069 clone PA557 HG008229.1 Homo septens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family B patient 038 clone PA295 ON037207.1 Trypanosoma cruzi strain PRM A70 minicircle kinetoplast complete sequence ON037224.1 Trypanosoma cruzi strain PRM A 94 minicircle kinetoplast complete sequence ON037220.1 Trypanosoma cruzi strain PRM A89 minicircle kinetoplast complete sequence ON037221.1 Trypanosoma cruzi strain PRM A90 minicircle kineto plast complete sequence ON037227.1 Trypanosoma cruzi strain PRM A109 minicircle kinetoplast complete sequence T ON037210.1 Trypanosoma cruzi strain PRM A73 minicircle kinetoplast complete sequence ON037219.1 Trypanosoma cruzi strain PRM A88 minicircle kinetoplast complete sequence ON037231.1 Trypanosoma cruzi strain PRM A 125 minicircle kinetoplast complete sequence ON037202.1 Trypanosoma cruzi strain PRM A 28 minicircle kinetoplast complete sequence ON037234.1 Trypanosoma cruzi strain PRM A141 minicircle kinetoplast complete sequence ON037213.1 Trypanosoma cruzi strain PRM A80 minicircle kinetoplast complete sequence ON037222.1 Trypanosom a cruzi strain PRM A91 minicircle kinetoplast com plete sequence ON037214.1 Trypanosoma cruzi strain PRM A83 minicircle kinetoplast complete sequence , ON037217.1 Trypanosoma cruzi strain PRM A86 minicircle kinetoplast complete sequence ON037225.1 Trypanosoma cruzi strain PRM A95 minicircle kinetoplast complete sequence ON037205.1 Trypanosoma cruzi strain PRM A58 minicircle kinetoplast complete sequence ON037215.1 Trypanosom a cruzi strain PRM A84 minicircle kinetoplast complete sequence ON037229.1 Trypanosoma cruzi strain PRM A123 minicircle kinetopiast complete sequence ON037232.1 Trypanosoma cruzi strain PRM A127 minicircle kinetoplast complete sequence 103 72 03.1 Trypanosoma cruzi strain PRM A 29 minicircle kinetopiast complete sequence 0N037230.1 Trypanosoma cruzi strain PRM A124 minicircle kinetoplast complete sequence ON037204.1 Trypanosoma cruzi strain PRM A48 minicircle kinetoplast complete sequence ON037226.1 Trypanosoma cruzi strain PRM A105 minicircle kinetoplast complete sequence N037223.1 Trypanosoma cruzi sarain PRM A92 minicircle kinetoplast complete sequence ON037233.1 Trypanosoma cruzi strain PRM A128 minicircle kinetoplast complete sequence ON037206.1 Trypanosoma cruzi strain PRM A69 minicircle kinetoplast complete sequence ON037216.1 Trypanosoma cruzi strain PRM A85 minicircle kinetoplast complete sequence N037218.1 Trypanosoma cruzi strain PRM A87 minicircle kinetoplast complete sequence ON037208.1 Trypanosoma cruzi strain PRM A71 minicircle kinetoplast complete sequence HG008325.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 082 clone PA528 HG008401.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 074 clone PA717 HG008468.1 Hom o sapiens genomic DNA comaining Trypanosom a cruzi kinetoplast minicircle DNA family C patient 083 clone PA654 HG008488.1 Hom o sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family C patient 087 clone PA666

4 FM 207299.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle and ORFc302 DNA case 1420 15 clone 302 — HG008705.1 Homo sapiens genomic DNA containing Trypanosoma cruzi kinetoplast minicircle DNA family D patent 082 clone FH184